PTPRJ

Summary

PTPRJ (protein tyrosine phosphatase receptor type J, HGNC:9673) is a protein-coding gene on chromosome 11p11.2, encoding Receptor-type tyrosine-protein phosphatase eta (Q12913). Tyrosine phosphatase which dephosphorylates or contributes to the dephosphorylation of CTNND1, FLT3, PDGFRB, MET, KDR, LYN, SRC, MAPK1, MAPK3, EGFR, TJP1, OCLN, PIK3R1 and PIK3R2.

The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes, including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region containing five fibronectin type III repeats, a single transmembrane region, and a single intracytoplasmic catalytic domain, and thus represents a receptor-type PTP. This protein is present in all hematopoietic lineages, and was shown to negatively regulate T cell receptor signaling possibly through interfering with the phosphorylation of Phospholipase C Gamma 1 and Linker for Activation of T Cells. This protein can also dephosphorylate the PDGF beta receptor, and may be involved in UV-induced signal transduction. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 5795 — RefSeq curated summary.

At a glance

• Gene–disease (curated): thrombocytopenia 10 (Moderate, GenCC) — +2 more curated relationships
• GWAS associations: 34
• Clinical variants (ClinVar): 255 total — 3 pathogenic
• Phenotypes (HPO): 17
• Druggable target: yes
• MANE Select transcript: NM_002843

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9673
Approved symbol	PTPRJ
Name	protein tyrosine phosphatase receptor type J
Location	11p11.2
Locus type	gene with protein product
Status	Approved
Aliases	DEP1, HPTPeta, CD148
Ensembl gene	ENSG00000149177
Ensembl biotype	protein_coding
OMIM	600925
Entrez	5795

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 5 protein_coding, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000418331, ENST00000440289, ENST00000526550, ENST00000527026, ENST00000527952, ENST00000534219, ENST00000698881

RefSeq mRNA: 2 — MANE Select: NM_002843 NM_001098503, NM_002843

CCDS: CCDS44596, CCDS7945

Canonical transcript exons

ENST00000418331 — 25 exons

Exon	Start	End
ENSE00000989130	48121003	48121266
ENSE00000989131	48123613	48123870
ENSE00000989132	48124968	48125186
ENSE00000989143	48150096	48150183
ENSE00001261565	48149447	48149488
ENSE00001609229	48163458	48163618
ENSE00001620947	48137003	48137281
ENSE00001635635	48164380	48164515
ENSE00001662326	48139486	48139776
ENSE00001695497	48153796	48153886
ENSE00001696064	48159930	48160049
ENSE00001702053	48145000	48145124
ENSE00001731519	48142919	48143050
ENSE00001746245	48155801	48155874
ENSE00001748566	48155985	48156119
ENSE00001755216	48136039	48136296
ENSE00001758576	48167204	48170839
ENSE00001793941	48144675	48144885
ENSE00001799954	48149990	48149998
ENSE00002279230	48130459	48130716
ENSE00002723238	48127780	48128043
ENSE00003499766	48112747	48112983
ENSE00003628576	48146876	48146963
ENSE00003650212	48110058	48110076
ENSE00003975062	47980559	47981008

Expression profiles

Bgee: expression breadth ubiquitous, 242 present calls, max score 96.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 24.5312 / max 3183.2093, expressed in 1656 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
114228	17.6820	1544
114229	5.7894	1393
114230	0.7952	465
114234	0.2646	91

Top tissues by expression

269 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	96.53	gold quality
leukocyte	CL:0000738	93.94	gold quality
monocyte	CL:0000576	93.92	gold quality
blood	UBERON:0000178	93.65	gold quality
parotid gland	UBERON:0001831	93.61	gold quality
renal medulla	UBERON:0000362	93.14	gold quality
pylorus	UBERON:0001166	92.67	gold quality
bone marrow cell	CL:0002092	92.60	gold quality
palpebral conjunctiva	UBERON:0001812	92.51	gold quality
jejunal mucosa	UBERON:0000399	91.90	gold quality
lateral nuclear group of thalamus	UBERON:0002736	91.76	gold quality
medial globus pallidus	UBERON:0002477	91.65	gold quality
globus pallidus	UBERON:0001875	91.19	gold quality
granulocyte	CL:0000094	90.89	gold quality
bone marrow	UBERON:0002371	90.87	gold quality
cardia of stomach	UBERON:0001162	90.74	gold quality
trigeminal ganglion	UBERON:0001675	90.71	gold quality
dorsal root ganglion	UBERON:0000044	90.05	gold quality
sural nerve	UBERON:0015488	89.79	gold quality
trabecular bone tissue	UBERON:0002483	89.67	gold quality
substantia nigra pars reticulata	UBERON:0001966	88.37	gold quality
cartilage tissue	UBERON:0002418	88.34	gold quality
inferior vagus X ganglion	UBERON:0005363	87.83	gold quality
duodenum	UBERON:0002114	87.55	gold quality
lateral globus pallidus	UBERON:0002476	87.53	gold quality
epithelial cell of pancreas	CL:0000083	87.42	silver quality
mucosa of sigmoid colon	UBERON:0004993	87.19	gold quality
dorsal plus ventral thalamus	UBERON:0001897	87.14	gold quality
colonic mucosa	UBERON:0000317	87.02	gold quality
seminal vesicle	UBERON:0000998	87.01	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	34.31
E-HCAD-35	yes	29.19
E-HCAD-25	yes	14.41
E-ANND-3	yes	11.56
E-GEOD-124858	no	96.68

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR5A1, SP1, TBX21

miRNA regulators (miRDB)

58 targeting PTPRJ, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-5580-3P	99.70	69.41	2052

Literature-anchored findings (GeneRIF, showing 40)

• In this paper, frequent deletion of PTPRJ is shown in human colon, lung, and breast cancers. (PMID:12089527)
• This protein is frequently deleted in human breast cancers. (PMID:12089527)
• CD148 and CD27 are expressed in a wide range of B cell non-Hodgkin’s lymphomas and do not serve to distinguish between neoplastic cells of naive and memory B cell derivation (PMID:12685844)
• DEP-1 is a negative regulator of cell proliferation, cell-substratum contacts, motility and chemotaxis in fibroblasts (PMID:14709717)
• propose that the expression and activation of DEP-1/PTPeta is required for somatostatin inhibition of glioma proliferation (PMID:15123617)
• A candidate tumor suppressor gene because its expression was blocked in rat and human thyroid transformed cells, and its restoration reverted their neoplastic phenotype. (PMID:15231692)
• genotypic profile of PTPRJ affects susceptibility to thyroid carcinomas, loss involved in thyroid carcinogenesis (PMID:15378013)
• single nucleotide polymorphisms in protein tyrosine phosphatase receptor type J is associated with breast cancer (PMID:16000320)
• Male, dizygotic twins were diagnosed with sensori-neural deafness at ages 5 and 21 months and later developed hypothyroidism at ages 24 and 28 months, respectively. Analysis for anti-DEP-1/CD148 autoantibodies described in Cogan syndrome proved positive. (PMID:16582570)
• Chemoprotective nutrients elevated transcription of endogenous DEP-1 mRNA & expression of DEP-1 protein. Upregulation of DEP-1 expression & inhibition of cell growth & migration may be a previously unrecognized mechanism of chemoprevention by nutrients. (PMID:16682945)
• These results demonstrate that CD148 may interact with and dephosphorylate p85 when it is phosphorylated and modulate the magnitude of phosphoinositide 3-kinase activity. (PMID:18348712)
• The translation of the region between AUG(191) and AUG(356) inhibits the overall expression of PTPRJ mRNA. (PMID:18603590)
• No significant evidence for the A1176C allele of PTPRJ or previously described haplotypes of tagSNPs in PTPRJ on CRC risk. (PMID:18843023)
• DEP-1 is a positive regulator of VEGF-mediated Src and Akt activation and endothelial cell survival. (PMID:18936167)
• The intact structure of the eighth fibronectin domain of PTPRJ is critical for its localization in plasma membrane and biological function. (PMID:19122201)
• DEP-1 can modify the phosphorylation state of tight junction proteins and play a role in regulating permeability. (PMID:19332538)
• CD148 may have a role in mantle cell lymphoma (PMID:19413345)
• DEP-1 inhibits the RAS pathway by direct dephosphorylation of ERK1/2 kinases (PMID:19494114)
• PTPRJ SNPs were found to influence susceptibility to a wide spectrum of cancers. (PMID:19672627)
• DEP-1 is a tumor suppressor that dephosphorylates and thereby stabilizes EGFR by hampering its ability to associate with the CBL-GRB2 ubiquitin ligase complex. (PMID:19836242)
• Data reveal PTPN2, PTPRJ and PTEN as potent regulators of Akt signalling which contribute to ameliorating the consequences of oncogenic K-Ras activity. (PMID:19922411)
• Therefore, the results reported here show that the homozygous genotype for Asp872 of PTPRJ is associated with an increased risk to develop papillary thyroid carcinoma. (PMID:20823296)
• PTPRJ is a candidate colorectal cancer susceptibility gene (PMID:21036128)
• We propose that positive regulation of adhesion signaling by DEP-1 is involved in inhibition of meningioma cell motility, and possibly tumor invasiveness. (PMID:21091576)
• DEP-1 is negatively regulating FLT3 signaling activity and that its loss may contribute to but is not sufficient for leukemogenic cell transformation. (PMID:21262971)
• That DEP-1 plays a biologic role in angiogenic endothelial cell behavior was demonstrated in endothelial cell migration, proliferation, and capillary-like tube formation assays in vitro (PMID:21304107)
• differential effects of CD148 in T cells and other leukocyte subsets (PMID:21543337)
• Here the protein tyrosine phosphatase receptor CD148 is shown to be a key intermediary in cell adhesion to S2ED, with downstream beta1 integrin-mediated adhesion and cytoskeletal organization (PMID:21813734)
• These findings provide evidence that CD148 functions as a receptor for TSP1 and mediates its inhibition of cell growth. (PMID:22308318)
• DEP-1 oxidation is a novel event contributing to cell transformation by FLT3 ITD. (PMID:22438257)
• Data indicate that miR-328 regulated PTPRJ expression, and suggest that the interaction of miR-328 with PTPRJ is responsible for miR-328-dependent increase of epithelial cell proliferation. (PMID:22564856)
• CD148 polymorphisms affect platelet activation and probably exert a protective effect on the risk of Heparin-induced thrombocytopenia in patients with antibodies to PF4/Heparin complexes. (PMID:22677127)
• These data indicate that PTPRJ may regulate differentiation of normal mammary epithelia and that dysregulation of protein localisation may be associated with tumorigenesis. (PMID:22815804)
• haplotypes in PTPRJ gene may play a role in susceptibility to Non-Hodgkin’s lymphoma, by affecting activation of PTPRJ in these B-cell lymphomas. (PMID:23341091)
• FLT3 is a bona fide substrate of DEP-1 and that interaction occurs mainly via an enzyme-substrate complex formation triggered by FLT3 ligand stimulation. (PMID:23650535)
• Data indicate that CD148 is upregulated in macrophages and T cells in rheumatoid arthritis (RA) samples, and its activity is enhanced by treatment with tumour necrosis factor alpha (TNFalpha), and reduced by synovial fluid or oxidising conditions. (PMID:24016860)
• our data support the notion of DEP-1 as positive functional regulator in vascular cerebral arteriogenesis, involving differential PDGF-B gene expression. (PMID:24027763)
• Phosphorylation of T1318 is part of a regulatory mechanism that channels the activity of DEP-1 towards Src to allow its optimal activation and the promotion of endothelial cell permeability. (PMID:24583284)
• CD148 tyrosine phosphatase promotes e-cadherin cell adhesion. (PMID:25386896)
• The expression profiles of DEP1 and B2MG correlate with increased cell senescence and survival in breast cancer. (PMID:25412306)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ptprja	ENSDARG00000033042
danio_rerio	ptprjb.2	ENSDARG00000086511
danio_rerio	ptprjb.1	ENSDARG00000091539
mus_musculus	Ptprj	ENSMUSG00000025314
rattus_norvegicus	Ptprj	ENSRNOG00000034025

Paralogs (35): PTPRN (ENSG00000054356), PTPRU (ENSG00000060656), PTPN3 (ENSG00000070159), PTPN21 (ENSG00000070778), PTPN18 (ENSG00000072135), PTPN23 (ENSG00000076201), PTPRH (ENSG00000080031), PTPRC (ENSG00000081237), PTPN4 (ENSG00000088179), PTPRS (ENSG00000105426), PTPRZ1 (ENSG00000106278), PTPN5 (ENSG00000110786), PTPN6 (ENSG00000111679), PTPRB (ENSG00000127329), PTPN12 (ENSG00000127947), PTPRE (ENSG00000132334), PTPRA (ENSG00000132670), PTPN22 (ENSG00000134242), PTPRF (ENSG00000142949), PTPN7 (ENSG00000143851), PTPRG (ENSG00000144724), PTPRO (ENSG00000151490), PTPN14 (ENSG00000152104), PTPRK (ENSG00000152894), PTPRR (ENSG00000153233), PTPRD (ENSG00000153707), PTPRN2 (ENSG00000155093), PTPN13 (ENSG00000163629), PTPN9 (ENSG00000169410), PTPRM (ENSG00000173482), PTPN2 (ENSG00000175354), PTPN11 (ENSG00000179295), PTPRT (ENSG00000196090), PTPN1 (ENSG00000196396), PTPN20 (ENSG00000204179)

Protein

Protein identifiers

Receptor-type tyrosine-protein phosphatase eta — Q12913 (reviewed: Q12913)

Alternative names: Density-enhanced phosphatase 1, HPTP eta, Protein-tyrosine phosphatase receptor type J

All UniProt accessions (4): Q12913, A0A8V8TP51, E9PJ83, E9PPH3

UniProt curated annotations — full annotation on UniProt →

Function. Tyrosine phosphatase which dephosphorylates or contributes to the dephosphorylation of CTNND1, FLT3, PDGFRB, MET, KDR, LYN, SRC, MAPK1, MAPK3, EGFR, TJP1, OCLN, PIK3R1 and PIK3R2. Plays a role in cell adhesion, migration, proliferation and differentiation. Has a role in megakaryocytes and platelet formation. Involved in vascular development. Regulator of macrophage adhesion and spreading. Positively affects cell-matrix adhesion. Positive regulator of platelet activation and thrombosis. Negative regulator of cell proliferation. Negative regulator of PDGF-stimulated cell migration; through dephosphorylation of PDGFR. Positive regulator of endothelial cell survival, as well as of VEGF-induced SRC and AKT activation; through KDR dephosphorylation. Negative regulator of EGFR signaling pathway; through EGFR dephosphorylation. Enhances the barrier function of epithelial junctions during reassembly. Negatively regulates T-cell receptor (TCR) signaling. Upon T-cell TCR activation, it is up-regulated and excluded from the immunological synapses, while upon T-cell-antigen presenting cells (APC) disengagement, it is no longer excluded and can dephosphorylate PLCG1 and LAT to down-regulate prolongation of signaling. Activates angiogenesis and cell migration. Downregulates the expression of the endothelial adhesion molecules ICAM1 and VCAM1.

Subunit / interactions. Monomer. Interacts with CTNNB1 (phosphorylated) and JUP (phosphorylated). Interacts with FLT3 (phosphorylated). Interacts with GAB1 and GRB2.

Subcellular location. Cell membrane. Cell projection. Ruffle membrane. Cell junction Secreted. Extracellular space.

Tissue specificity. Expressed in the promyelocytic cell line HL-60, the granulocyte-macrophage colony-stimulating factor-dependent leukemic cell line F-36P, and the IL3 and erythropoietin-dependent leukemic cell line F-36E. Expressed predominantly in epithelial cells and lymphocytes. Enhanced expression at high cell density. Expressed in the brain.

Post-translational modifications. N- and O-glycosylated. N-glycosylated.

Disease relevance. Thrombocytopenia 10 (THC10) [MIM:620484] A form of thrombocytopenia, a hematologic disorder defined by a decrease in the number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. THC10 is an autosomal recessive form characterized by decreased numbers of platelets apparent from birth or early childhood. The disease is caused by variants affecting the gene represented in this entry.

Miscellaneous. Expressed in several normal and cancer cell lines, including A549, HUVEC, MCF7, HeLa, A172 and ADF cells (at protein level). Up-regulated in high-grade glioma samples.

Similarity. Belongs to the protein-tyrosine phosphatase family. Receptor class 3 subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q12913-1	1	yes
Q12913-2	2, sPTPRJ
Q12913-3	3

RefSeq proteins (2): NP_001091973, NP_002834* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000242	PTP_cat	Domain
IPR000387	Tyr_Pase_dom	Domain
IPR003595	Tyr_Pase_cat	Domain
IPR003961	FN3_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR016130	Tyr_Pase_AS	Active_site
IPR029021	Prot-tyrosine_phosphatase-like	Homologous_superfamily
IPR036116	FN3_sf	Homologous_superfamily
IPR041201	PTPRJ_TM	Domain
IPR050713	RTP_Phos/Ushers	Family

Pfam: PF00041, PF00102, PF18861

Enzyme classification (BRENDA):

• EC 3.1.3.48 — protein-tyrosine-phosphatase (BRENDA: 59 organisms, 501 substrates, 1326 inhibitors, 270 Km, 165 kcat entries)

Substrate kinetics (BRENDA)

70 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4-NITROPHENYL PHOSPHATE	0.0008–148	84
6,8-DIFLUORO-4-METHYLUMBELLIFERYL PHOSPHATE	0.0039–0.862	27
P-NITROPHENYL PHOSPHATE	0.0024–10	20
DADEPYLIPQQG	0.0003–0.1	12
PHOSPHOTYROSINE	0.012–30	11
LYSOZYME	0.0003–0.012	5
MYELIN BASIC PROTEIN	0.0001–0.022	5
ACETYL-DADEPY-NH2	0.0228–0.219	4
ACETYL-DADEPYL-NH2	1.1–97.5	4
4,6,8-TRIMETHYL-2-OXO-2H-CHROMEN-7-YL DIHYDROGEN	0.02–0.156	3
SASASPYSASA	0.53–2.3	3
1-NAPHTHYL PHOSPHATE	1.19–1.88	2
3,6-FLUORESCEIN DIPHOSPHATE	15–19	2
4-METHYLUMBELLIFERYL PHOSPHATE	0.953–2.41	2
BOVINE SERUM ALBUMIN	0.0001–0.0003	2

Catalyzed reactions (Rhea), 1 shown:

• O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate (RHEA:10684)

UniProt features (123 total): glycosylation site 34, strand 33, domain 10, helix 9, sequence variant 7, turn 5, sequence conflict 5, binding site 3, splice variant 3, mutagenesis site 3, region of interest 2, compositionally biased region 2, topological domain 2, signal peptide 1, chain 1, active site 1, modified residue 1, transmembrane region 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
7U01	X-RAY DIFFRACTION	2.3
2NZ6	X-RAY DIFFRACTION	2.3
2CFV	X-RAY DIFFRACTION	2.5
7U08	X-RAY DIFFRACTION	3.31
2DLE	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q12913-F1	78.58	0.40

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 1239 (phosphocysteine intermediate)

Ligand- & substrate-binding residues (3): 1205; 1239–1245; 1283

Post-translational modifications (1): 1009

Glycosylation sites (34): 72, 82, 93, 104, 142, 172, 192, 231, 258, 278, 342, 351, 376, 391, 396, 413, 431, 501, 525, 536 …

Mutagenesis-validated functional residues (3):

Position	Phenotype
1016	80% decrease in interaction with mapk1 and mapk3.
1205	substrate trapping with much higher affinity for substrate.
1239	catalytically inactive and substrate trapping with higher affinity for substrate.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-202427	Phosphorylation of CD3 and TCR zeta chains
R-HSA-6798695	Neutrophil degranulation
R-HSA-6807004	Negative regulation of MET activity
R-HSA-9706369	Negative regulation of FLT3

MSigDB gene sets: 600 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GSE45365_NK_CELL_VS_CD8_TCELL_UP, GOBP_PLATELET_DERIVED_GROWTH_FACTOR_RECEPTOR_SIGNALING_PATHWAY, GOBP_REGULATION_OF_T_CELL_RECEPTOR_SIGNALING_PATHWAY, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_NEGATIVE_REGULATION_OF_MAP_KINASE_ACTIVITY, GOBP_REGULATION_OF_ANTIGEN_RECEPTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, REACTOME_INNATE_IMMUNE_SYSTEM, MYOGENIN_Q6, GOBP_POSITIVE_REGULATION_OF_ENDOCYTOSIS, GOBP_REGULATION_OF_CALCIUM_MEDIATED_SIGNALING, YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_REGULATION_OF_ERBB_SIGNALING_PATHWAY, GOBP_MYELOID_LEUKOCYTE_MIGRATION

GO Biological Process (47): angiogenesis (GO:0001525), vasculogenesis (GO:0001570), signal transduction (GO:0007165), axon guidance (GO:0007411), heart development (GO:0007507), blood coagulation (GO:0007596), negative regulation of cell population proliferation (GO:0008285), positive regulation of platelet activation (GO:0010572), negative regulation of platelet-derived growth factor receptor signaling pathway (GO:0010642), positive regulation of macrophage chemotaxis (GO:0010759), cytokine-mediated signaling pathway (GO:0019221), regulation of cell adhesion (GO:0030155), B cell differentiation (GO:0030183), platelet formation (GO:0030220), negative regulation of cell growth (GO:0030308), negative regulation of cell migration (GO:0030336), positive regulation of tumor necrosis factor production (GO:0032760), peptidyl-tyrosine dephosphorylation (GO:0035335), negative regulation of epidermal growth factor receptor signaling pathway (GO:0042059), glucose homeostasis (GO:0042593), negative regulation of vascular permeability (GO:0043116), negative regulation of MAP kinase activity (GO:0043407), positive regulation of MAPK cascade (GO:0043410), positive regulation of cell adhesion (GO:0045785), negative regulation of insulin receptor signaling pathway (GO:0046627), platelet-derived growth factor receptor signaling pathway (GO:0048008), oligodendrocyte differentiation (GO:0048709), positive regulation of phagocytosis (GO:0050766), positive regulation of calcium-mediated signaling (GO:0050850), T cell receptor signaling pathway (GO:0050852), negative regulation of T cell receptor signaling pathway (GO:0050860), positive chemotaxis (GO:0050918), positive regulation of focal adhesion assembly (GO:0051894), positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051897), negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051898), contact inhibition (GO:0060242), positive regulation of Fc receptor mediated stimulatory signaling pathway (GO:0060369), positive regulation of cell-matrix adhesion (GO:0001954), immune system process (GO:0002376), protein dephosphorylation (GO:0006470)

GO Molecular Function (12): protein tyrosine phosphatase activity (GO:0004725), platelet-derived growth factor receptor binding (GO:0005161), beta-catenin binding (GO:0008013), phosphatase activity (GO:0016791), protein kinase binding (GO:0019901), gamma-catenin binding (GO:0045295), cadherin binding (GO:0045296), mitogen-activated protein kinase binding (GO:0051019), delta-catenin binding (GO:0070097), phosphoprotein phosphatase activity (GO:0004721), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (15): immunological synapse (GO:0001772), nucleoplasm (GO:0005654), nucleolus (GO:0005730), plasma membrane (GO:0005886), cell-cell junction (GO:0005911), cell surface (GO:0009986), nuclear body (GO:0016604), cell junction (GO:0030054), ruffle membrane (GO:0032587), specific granule membrane (GO:0035579), extracellular exosome (GO:0070062), extracellular region (GO:0005576), membrane (GO:0016020), cell projection (GO:0042995), anchoring junction (GO:0070161)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
TCR signaling	1
Innate Immune System	1
Signaling by MET	1
FLT3 Signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	7
protein binding	3
blood vessel morphogenesis	2
anatomical structure formation involved in morphogenesis	2
regulation of cellular process	2
negative regulation of cellular process	2
nuclear lumen	2
intracellular membraneless organelle	2
cell differentiation	1
cell communication	1
cellular process	1
signaling	1
cellular response to stimulus	1
axonogenesis	1
neuron projection guidance	1
animal organ development	1
circulatory system development	1
hemostasis	1
wound healing	1
coagulation	1
cell population proliferation	1
regulation of cell population proliferation	1
regulation of platelet activation	1
platelet activation	1
positive regulation of cell activation	1
negative regulation of signal transduction	1
regulation of platelet-derived growth factor receptor signaling pathway	1
platelet-derived growth factor receptor signaling pathway	1
positive regulation of leukocyte chemotaxis	1
regulation of macrophage chemotaxis	1
macrophage chemotaxis	1
regulation of granulocyte chemotaxis	1
positive regulation of macrophage migration	1
cell surface receptor signaling pathway	1
cellular response to cytokine stimulus	1
cell adhesion	1
lymphocyte differentiation	1
B cell activation	1
myeloid cell differentiation	1
platelet morphogenesis	1

Protein interactions and networks

STRING

1486 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PTPRJ	PTS	Q03393	825
PTPRJ	THBS1	P07996	798
PTPRJ	SDC2	P34741	789
PTPRJ	CDH5	P33151	785
PTPRJ	SAP30	O75446	779
PTPRJ	FYN	P06241	703
PTPRJ	CTNNB1	P35222	684
PTPRJ	CSK	P41240	621
PTPRJ	LCK	P06239	621
PTPRJ	KDR	P35968	617
PTPRJ	CTNND1	O60716	611
PTPRJ	CDH17	Q12864	606
PTPRJ	MET	P08581	602
PTPRJ	SUDS3	Q9H7L9	581
PTPRJ	FLT3	P36888	549

IntAct

143 interactions, top by confidence:

A	B	Type	Score
PTPRJ	MET	psi-mi:“MI:0915”(physical association)	0.730
MET	PTPRJ	psi-mi:“MI:0203”(dephosphorylation reaction)	0.730
MET	PTPRJ	psi-mi:“MI:0915”(physical association)	0.730
PDGFRB	PTPRJ	psi-mi:“MI:0203”(dephosphorylation reaction)	0.720
PDGFRB	PTPRJ	psi-mi:“MI:0915”(physical association)	0.720
PTPRJ	CTNND1	psi-mi:“MI:0203”(dephosphorylation reaction)	0.720
CTNND1	PTPRJ	psi-mi:“MI:0915”(physical association)	0.720
PTPRJ	CTNND1	psi-mi:“MI:0403”(colocalization)	0.720
PTPRJ	CTNND1	psi-mi:“MI:0915”(physical association)	0.720
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
PTPRJ	MAPK3	psi-mi:“MI:0407”(direct interaction)	0.700
PTPRJ	MAPK3	psi-mi:“MI:0914”(association)	0.700
MAPK3	PTPRJ	psi-mi:“MI:0914”(association)	0.700
PTPRJ	PTPRJ	psi-mi:“MI:0407”(direct interaction)	0.660
PTPRJ	PTPRJ	psi-mi:“MI:0914”(association)	0.660
PTPRJ	PTPRJ	psi-mi:“MI:0203”(dephosphorylation reaction)	0.660
KDR	PTPRJ	psi-mi:“MI:0203”(dephosphorylation reaction)	0.650
PTPRJ	KDR	psi-mi:“MI:0915”(physical association)	0.650
STX7	SNAP23	psi-mi:“MI:0914”(association)	0.640
PTPRJ	FLT1	psi-mi:“MI:0203”(dephosphorylation reaction)	0.620
FLT1	PTPRJ	psi-mi:“MI:0203”(dephosphorylation reaction)	0.620
PTPRJ	CTNNB1	psi-mi:“MI:0915”(physical association)	0.610

BioGRID (125): PTPRJ (Affinity Capture-MS), PTPRJ (Affinity Capture-MS), PTPRJ (Affinity Capture-MS), BAP1 (Two-hybrid), CASC3 (Two-hybrid), CYP17A1 (Two-hybrid), EPSTI1 (Two-hybrid), HOXC6 (Two-hybrid), KLK7 (Two-hybrid), KLK9 (Two-hybrid), LYPD3 (Two-hybrid), PRDM14 (Two-hybrid), TRIM25 (Two-hybrid), PTPRJ (Proximity Label-MS), RINT1 (Proximity Label-MS)

ESM2 similar proteins: A1L3I3, A2A9G7, A6QNY1, A6QPL2, D3ZF92, O35664, O75509, O88324, P03173, P03218, P06475, P0C192, P0CC10, P10228, P13374, P28986, P98154, P98162, Q01151, Q12913, Q1L867, Q1RMT9, Q29000, Q3TR08, Q56A20, Q5BIR3, Q5R7R7, Q5RCS3, Q5RD34, Q5VUB5, Q61003, Q6DF55, Q6RJQ3, Q7TMJ8, Q8CFD9, Q8K3V5, Q8K4Z2, Q8NAU1, Q8TBC3, Q91ZV2

Diamond homologs: A0A6I8TCE0, A1L1L3, A2ALK8, A4IFW2, B0V2N1, B0X4T2, B1AUH1, B2GV87, B2RU80, B3DK56, B9EKR1, E9Q0N2, E9Q612, F1NWE3, G5EC24, G5EGJ9, H2KZM6, O02695, O08617, O13016, O35239, O55082, P06800, P16620, P17706, P18031, P18052, P18433, P20417, P23467, P23468, P23469, P23470, P23471, P26045, P28191, P29074, P29350, P29351, P29352

SIGNOR signaling

55 interactions.

A	Effect	B	Mechanism
PTPRJ	down-regulates	FLT1	dephosphorylation
PTPRJ	“down-regulates activity”	MAPK1	dephosphorylation
PTPRJ	down-regulates	MAPK1	dephosphorylation
PTPRJ	down-regulates	MAPK3	dephosphorylation
PTPRJ	down-regulates	LAT	dephosphorylation
PTPRJ	down-regulates	PLCG1	dephosphorylation
PTPRJ	down-regulates	RET	dephosphorylation
PTPRJ	down-regulates	PIK3R1	dephosphorylation
PTPRJ	down-regulates	KDR	dephosphorylation
PTPRJ	down-regulates	INSR	dephosphorylation
PTPRJ	“down-regulates activity”	LAT	dephosphorylation
PTPRJ	“up-regulates quantity by stabilization”	EGFR	dephosphorylation
PTPRJ	“down-regulates activity”	RET	dephosphorylation
PTPRJ	“down-regulates activity”	MET	dephosphorylation
PTPRJ	“down-regulates activity”	PDGFRB	dephosphorylation
PTPRJ	unknown	PLCG1	dephosphorylation
PTPRJ	“down-regulates activity”	KDR	dephosphorylation
PTPRJ	“down-regulates activity”	CBL
PTPRJ	down-regulates	PI3K	dephosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 104 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Bacterial Infection Pathways	6	24.9×	2e-05
Negative regulation of the PI3K/AKT network	6	20.6×	4e-05
Signaling by RAF1 mutants	6	20.6×	4e-05
Signaling by high-kinase activity BRAF mutants	5	19.6×	2e-04
Signaling by moderate kinase activity BRAF mutants	6	18.8×	5e-05
Paradoxical activation of RAF signaling by kinase inactive BRAF	6	18.8×	5e-05
Signaling downstream of RAS mutants	6	18.8×	5e-05
Signaling by SCF-KIT	6	18.4×	5e-05

GO biological processes:

GO term	Partners	Fold	FDR
Schwann cell development	5	54.9×	5e-06
peptidyl-tyrosine phosphorylation	6	26.3×	2e-05
insulin-like growth factor receptor signaling pathway	5	25.8×	8e-05
cell surface receptor protein tyrosine kinase signaling pathway	12	21.7×	3e-10
T cell costimulation	5	19.5×	2e-04
epidermal growth factor receptor signaling pathway	7	18.1×	2e-05
myelination	6	15.7×	1e-04
protein autophosphorylation	10	15.1×	3e-07

Disease & clinical

Clinical variants and AI predictions

ClinVar

255 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	161
Likely benign	41
Benign	9

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
2577546	NM_002843.4(PTPRJ):c.97-2A>G	Pathogenic
2577547	NM_002843.4(PTPRJ):c.1875del	Pathogenic
8689	NM_002843.4(PTPRJ):c.640C>T (p.Arg214Cys)	Pathogenic

SpliceAI

4979 predictions. Top by Δscore:

Variant	Effect	Δscore
11:47981007:AGGT:A	donor_loss	1.0000
11:47981008:GGTA:G	donor_loss	1.0000
11:47981009:GT:G	donor_loss	1.0000
11:47981010:T:G	donor_loss	1.0000
11:48082194:G:GT	donor_gain	1.0000
11:48086730:G:GT	donor_gain	1.0000
11:48110077:G:GG	donor_gain	1.0000
11:48112743:A:AG	acceptor_gain	1.0000
11:48112744:T:G	acceptor_gain	1.0000
11:48112745:A:AG	acceptor_gain	1.0000
11:48112746:G:GG	acceptor_gain	1.0000
11:48112980:ACTGG:A	donor_loss	1.0000
11:48112984:G:GG	donor_gain	1.0000
11:48112984:GTAAG:G	donor_loss	1.0000
11:48112985:T:A	donor_loss	1.0000
11:48125078:G:GT	donor_gain	1.0000
11:48125078:G:T	donor_gain	1.0000
11:48125182:GACAA:G	donor_gain	1.0000
11:48125187:G:GG	donor_gain	1.0000
11:48127778:A:AG	acceptor_gain	1.0000
11:48127778:A:AT	acceptor_loss	1.0000
11:48127778:AGAT:A	acceptor_gain	1.0000
11:48127779:G:GG	acceptor_gain	1.0000
11:48127779:GAT:G	acceptor_gain	1.0000
11:48127779:GATG:G	acceptor_gain	1.0000
11:48128044:G:GG	donor_gain	1.0000
11:48130455:A:AG	acceptor_gain	1.0000
11:48130456:T:G	acceptor_gain	1.0000
11:48130457:A:AG	acceptor_gain	1.0000
11:48130458:G:GG	acceptor_gain	1.0000

AlphaMissense

8738 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:48150167:T:C	F1041S	1.000
11:48163506:T:A	W1203R	1.000
11:48163506:T:C	W1203R	1.000
11:48163508:G:C	W1203C	1.000
11:48163508:G:T	W1203C	1.000
11:48164394:G:C	R1245T	1.000
11:48164394:G:T	R1245M	1.000
11:48164395:G:C	R1245S	1.000
11:48164395:G:T	R1245S	1.000
11:48150167:T:G	F1041C	0.999
11:48153800:T:C	L1048P	0.999
11:48153865:C:A	R1070S	0.999
11:48156051:T:A	W1124R	0.999
11:48156051:T:C	W1124R	0.999
11:48163515:C:G	H1206D	0.999
11:48163516:A:C	H1206P	0.999
11:48163614:T:C	C1239R	0.999
11:48163616:C:G	C1239W	0.999
11:48163617:A:C	S1240R	0.999
11:48164380:T:A	S1240R	0.999
11:48164380:T:G	S1240R	0.999
11:48164382:C:A	A1241D	0.999
11:48164384:G:T	G1242W	0.999
11:48164385:G:A	G1242E	0.999
11:48164390:G:A	G1244R	0.999
11:48164390:G:C	G1244R	0.999
11:48164391:G:A	G1244E	0.999
11:48164391:G:T	G1244V	0.999
11:48164393:A:G	R1245G	0.999
11:48164399:G:C	G1247R	0.999

dbSNP variants (sampled 300 via entrez): RS1000022246 (11:48135405 G>A,C), RS1000025892 (11:48150917 T>C), RS1000030518 (11:48135211 G>C,T), RS1000069164 (11:48092989 T>C), RS1000087684 (11:47995831 A>G), RS1000088909 (11:48084431 G>A,C), RS1000091041 (11:48138822 A>T), RS1000097277 (11:48040340 C>A), RS1000144210 (11:48112248 G>A), RS1000165551 (11:48066367 T>C,G), RS1000176070 (11:48064400 C>T), RS1000183158 (11:48024583 A>G), RS1000206950 (11:48159653 G>A,T), RS1000207204 (11:48022746 C>T), RS1000232262 (11:48161925 T>A,G)

Disease associations

OMIM: gene MIM:600925 | disease phenotypes: MIM:620484, MIM:114500

GenCC curated gene-disease

Disease	Classification	Inheritance
thrombocytopenia 10	Moderate	Autosomal recessive
colorectal cancer	No Known Disease Relationship	Unknown

ClinGen Gene-Disease Validity (2)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
hereditary nonpolyposis colon cancer	Limited	AD
thrombocytopenia 10	Limited	AR

Mondo (4): thrombocytopenia 10 (MONDO:0957578), colon carcinoma (MONDO:0002032), colorectal cancer (MONDO:0005575), aortic valve stenosis (MONDO:0042981)

Orphanet (1): NON RARE IN EUROPE: Colorectal cancer (Orphanet:466667)

HPO phenotypes

17 total (18 of 17 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0000132	Menorrhagia
HP:0000967	Petechiae
HP:0000978	Bruising susceptibility
HP:0001442	Typified by somatic mosaicism
HP:0001873	Thrombocytopenia
HP:0001892	Abnormal bleeding
HP:0002891	Uterine leiomyosarcoma
HP:0003003	Colon cancer
HP:0003577	Congenital onset
HP:0004406	Spontaneous, recurrent epistaxis
HP:0005537	Decreased mean platelet volume
HP:0005584	Renal cell carcinoma
HP:0006716	Hereditary nonpolyposis colorectal carcinoma
HP:0006740	Transitional cell carcinoma of the bladder
HP:0006753	Neoplasm of the stomach
HP:0001650	Aortic valve stenosis

GWAS associations

34 associations (top):

Study	Trait	p-value
GCST001049_3	D-dimer levels	9.000000e-06
GCST001320_28	Acute lymphoblastic leukemia (childhood)	1.000000e-06
GCST001320_3	Acute lymphoblastic leukemia (childhood)	5.000000e-07
GCST001956_75	Height	7.000000e-12
GCST002580_1	Intraocular pressure	1.000000e-11
GCST002647_41	Height	2.000000e-20
GCST005170_48	Intraocular pressure	2.000000e-07
GCST005580_145	Intraocular pressure	2.000000e-30
GCST005580_213	Intraocular pressure	1.000000e-22
GCST006394_90	Intraocular pressure	4.000000e-23
GCST006412_121	Intraocular pressure	1.000000e-27
GCST006585_2483	Blood protein levels	8.000000e-07
GCST006944_49	Experiencing mood swings	3.000000e-08
GCST006979_791	Heel bone mineral density	4.000000e-12
GCST007559_27	Sleep duration (short sleep)	4.000000e-08
GCST007825_4	Alzheimer’s disease or fasting glucose levels (pleiotropy)	3.000000e-16
GCST008163_268	Height	1.000000e-06
GCST008363_83	Offspring birth weight	4.000000e-11
GCST009413_12	Intraocular pressure	2.000000e-09
GCST009685_9	Hypertension	2.000000e-09
GCST009725_11	Intraocular pressure	6.000000e-23
GCST010002_238	Refractive error	2.000000e-14
GCST011126_23	Caffeine consumption from coffee or tea	1.000000e-08
GCST012353_37	Serum metabolite concentrations in chronic kidney disease	5.000000e-14
GCST90002385_201	High light scatter reticulocyte count	1.000000e-11
GCST90002386_351	High light scatter reticulocyte percentage of red cells	1.000000e-14
GCST90002388_536	Lymphocyte count	5.000000e-43
GCST90002395_83	Mean platelet volume	2.000000e-15
GCST90002396_465	Mean reticulocyte volume	5.000000e-18
GCST90002397_523	Mean spheric corpuscular volume	2.000000e-19

EFO canonical traits (13, from GWAS)

EFO ID	Trait name
EFO:0004507	D dimer measurement
EFO:0004695	intraocular pressure measurement
EFO:0008475	mood instability measurement
EFO:0009270	heel bone mineral density
EFO:0004344	birth weight
EFO:0005939	parental genotype effect measurement
EFO:0006781	coffee consumption measurement
EFO:0010091	tea consumption measurement
EFO:0007986	reticulocyte count
EFO:0004587	lymphocyte count
EFO:0010701	mean reticulocyte volume
EFO:0004736	aspartate aminotransferase measurement
EFO:0004533	alkaline phosphatase measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001024	Aortic Valve Stenosis	C14.280.484.048.750; C14.280.955.249

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3692 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Receptor tyrosine phosphatase (RTP) family

Binding affinities (BindingDB)

1 measured of 3 human assays (3 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
US8987474, NSC-87877	IC50	84500 nM	US-8987474: Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, decreases expression, decreases methylation, affects cotreatment	4
Benzo(a)pyrene	decreases expression, increases expression, increases methylation	3
Acetaminophen	decreases expression, increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Aflatoxin B1	decreases methylation, decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
bisphenol A	decreases methylation, affects cotreatment	1
arsenite	increases methylation	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
benzo(e)pyrene	decreases methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
mono(2-ethyl-5-hydroxyhexyl) phthalate	affects methylation, increases abundance	1
dorsomorphin	affects cotreatment, decreases expression	1
apple polyphenol extract	increases expression	1
Sunitinib	decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Leflunomide	increases expression	1
Arsenic	affects methylation	1
Cisplatin	decreases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, increases expression	1
Etoposide	decreases expression	1
Gallic Acid	decreases expression	1
Hydralazine	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
Methapyrilene	decreases methylation	1
Methotrexate	increases expression	1

ChEMBL screening assays

5 unique, capped per target: 4 binding, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3707957	Binding	Inhibition Assay: NSC-87877 ranked among top 10% (175th) of the compounds with the best GLIDE scores for the docking to the human Shp2 PTP domain in our virtual screening of 2368 3D structures derived from the NCI Diversity Set. Computer do	Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs
CHEMBL4626301	ADMET	Inhibition of DEP1 (unknown origin) expressed in Escherichia coli BL21 using p-nitrophenyl phosphate as substrate measured after 30 mins by UV-vis spectrophotometric method	Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B. — J Med Chem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TH67	HAP1 PTPRJ (-) 1	Cancer cell line	Male
CVCL_XS04	HAP1 PTPRJ (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

598 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00114829	PHASE4	UNKNOWN	Preoperative Assessment of Colon Tumor
NCT00114842	PHASE4	COMPLETED	Magnetic Resonance (MR) Colonography With Fecal Tagging
NCT00114946	PHASE4	TERMINATED	A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer
NCT00122720	PHASE4	COMPLETED	The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery
NCT00129870	PHASE4	TERMINATED	CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer
NCT00138060	PHASE4	COMPLETED	Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
NCT00216424	PHASE4	TERMINATED	Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma
NCT00327093	PHASE4	TERMINATED	Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
NCT00332943	PHASE4	COMPLETED	MR Colonography With Fecal Tagging. Barium vs. BariumFerumoxsil
NCT00441311	PHASE4	COMPLETED	Dissemination of Colorectal Cancer Screening to Primary Care Physicians
NCT00460837	PHASE4	WITHDRAWN	Comparison of Bowel Preparation in Virtual Colonoscopy (VC) - Patient Experience
NCT00473980	PHASE4	COMPLETED	Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients
NCT00488904	PHASE4	COMPLETED	Omega-3 Fatty Acids and Postoperative Complications After Colorectal Surgery
NCT00496678	PHASE4	COMPLETED	Trial of Patient Navigation-Activation
NCT00502671	PHASE4	COMPLETED	A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
NCT00559676	PHASE4	COMPLETED	Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
NCT00577031	PHASE4	COMPLETED	OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
NCT00626054	PHASE4	COMPLETED	Comparison of Two Methods of Administration of a PEG Solution
NCT00812864	PHASE4	COMPLETED	Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)
NCT00868569	PHASE4	UNKNOWN	Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer
NCT00868816	PHASE4	COMPLETED	Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles
NCT00874406	PHASE4	UNKNOWN	Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer
NCT00928928	PHASE4	COMPLETED	Oxidative Stress Markers in Open and Laparoscopic Colectomy for Cancer
NCT00942461	PHASE4	COMPLETED	Inflammatory Response in Laparoscopic and Open Colectomy
NCT01023633	PHASE4	UNKNOWN	OPTIMOX1 in Chinese mCRC Patients
NCT01271582	PHASE4	UNKNOWN	Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
NCT01315990	PHASE4	UNKNOWN	FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema
NCT01493713	PHASE4	COMPLETED	Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer
NCT01609660	PHASE4	COMPLETED	Impact of Probiotics on the Intestinal Microbiota
NCT01641458	PHASE4	COMPLETED	Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients
NCT01689792	PHASE4	COMPLETED	A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)
NCT01695772	PHASE4	COMPLETED	A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer
NCT01695863	PHASE4	COMPLETED	Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep
NCT01706822	PHASE4	TERMINATED	Radial Reload Laparoscopic LAR Case Series
NCT01740947	PHASE4	TERMINATED	Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?
NCT01831310	PHASE4	COMPLETED	Nutrition for Colorectal Cancer Patients and Neutrophil Functions
NCT01841294	PHASE4	UNKNOWN	NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery
NCT01959061	PHASE4	UNKNOWN	Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
NCT02032953	PHASE4	UNKNOWN	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia
NCT02567331	PHASE4	COMPLETED	A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer